J.J. Finkelstein, President and CEO of RegeneRx Biopharmaceuticals, Inc. 00:00:00

Share On Facebook Share On Twitter

RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications

Recent Videos